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Since the Federal Drug and Administration (FDA) approvalof bevacizumab in 2006, several other angiogenesis in-
hibitors are under investigation in the treatment of lung
cancer. At the 11th annual “Targeted Therapies of The
Treatment of Lung Cancer” meeting in Santa Monica, Dr.
Roy Herbst provided an overview of angiogenesis inhibitors
and a brief update of their role in lung cancer treatment.
His introduction was followed by 10 presentations of
specific inhibitors of angiogenesis being studied in non-
small cell lung cancer (NSCLC) in various stages of
clinical development.
Angiogenesis targets include vascular endothelial
growth factor (VEGF), fibroblast growth factor receptor
(FGFR), platelet-derived growth factor (PDGF), Notch/Del-
ta-like ligand 4 (DLL-4) signaling, and Tie2/Angiopoietin
signaling. Vascular-targeting agents are further composed of
antibodies, vascular disrupting agents (VDAs), and tyrosine
kinase inhibitors (TKIs). Given the side effects and the
emergence of resistance to antiangiogenic therapies, ques-
tions remain regarding how to best combine angiogenesis
inhibitors and their role with conventional therapies.
Summary of Presentations
Dr. Glen Goss discussed cediranib, a potent inhibitor of
vascular endothelial growth factor receptor (VEGFR), which
has been evaluated in various different tumors, including
advanced NSCLC. In the phase II BR.24 trial by the National
Cancer Institute of Canada Clinical Trials Group (NCIC
CTG), patients with advanced NSCLC were randomized to
receive carboplatin/paclitaxel plus cediranib versus placebo.
Those patients receiving cediranib (given at a dose of 30 mg)
had a higher response rate (RR) (38 versus 16%) with a trend
toward improvement in progression-free survival (PFS) (HR:
0.77, 95% CI: 0.56–1.08).1 Nevertheless, patients receiving
cediranib in this trial were found to have significantly increased
toxicity, including hypertension, hypothyroidism, hand-foot syn-
drome, and gastrointestinal (GI) effects. Given this finding, the
ongoing NCIC CTG BR.29 phase II/III trial uses a reduced dose
of cediranib at 20 mg daily and has a planned safety analysis
after 50 patients have been accrued and a planned interim
analysis on the first 260 patients. Assuming cediranib is felt to be
safe and meets the minimum hazard ratio of less than 0.7 at the
time of the interim analysis, the trial will be continued to
complete the phase III accrual goal of 750 patients.
Dr. Joan Schiller outlined the trials involving sunitinib
and axitinib, which are both VEGFR TKIs targeting VEGFR-1,
VEGFR-2, and VEGFR-3. In addition, sunitinib targets platelet-
derived growth factor receptor beta (PDGFR-b), KIT, RET, and
FLT3. In a phase III trial, patients with NSCLC undergoing
second- or third-line treatment were randomized to receive
sunitinib plus erlotinib versus placebo plus erlotinib. The addi-
tion of sunitinib to erlotinib significantly improved PFS, al-
though not overall survival (OS), which was the primary end
point of the trial.2 Ongoing Cancer and Leukemia Group B
(CALGB) studies are evaluating sunitinib either in com-
bination with pemetrexed or as maintenance therapy in
NSCLC and in untreated small cell lung cancer (SCLC). In
three different phase II trials, axitinib was combined with
chemotherapy in patients with stage IIIB/IV nonsquamous
NSCLC with results pending at this time.
Dr. John Heymach reviewed pazopanib and XL647 in
NSCLC. Pazopanib, an oral VEGFR TKI approved in renal
cell carcinoma (RCC), was first studied in the preoperative
setting in patients with stage I/II NSCLC with 86% of
patients displaying tumor shrinkage.3 These results led to
pazopanib being studied in the adjuvant and refractory setting
in several ongoing studies. XL647 inhibits epidermal growth
factor receptor (EGFR), Her2, and VEGFR-2 and showed
moderate activity in EGFR mutants in a phase II trial,
although the future of this drug remains uncertain.4
Dr. Heather Wakelee discussed BIBF1120, a potent in-
hibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, and
FGFR, which is under investigation in two ongoing phase III
trials in the second-line setting, in combination with either
pemetrexed or docetaxel. In the initial studies, BIBF1120 was
associated with a dose-limiting toxicity of transaminitis and
patients developed mostly GI toxicities with minimal hyperten-
sion seen.
Dr. Primo Lara updated data regarding ASA 404, a
vascular disrupting agent, which demonstrated promising
results as frontline therapy in combination with carboplatin/
paclitaxel in the phase II setting.5 Nevertheless, the AT-
TRACT-1 and ATTRACT-2 phase III studies evaluating
ASA 404 in combination with chemotherapy in the first- and
second-line settings, respectively, were both discontinued in
2010 after interim analyses revealed an unlikely benefit with
the addition of ASA 404.
Dr. Karen Kelly discussed tivozanib, a potent, selective
VEGFR TKI, which has shown encouraging results in RCC
and is being compared with sorafenib in frontline treatment of
RCC in the global, randomized phase III TIVO-1 trial that
recently completed accrual. In lung cancer, tivozanib is cur-
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rently being studied in a phase IB/IIA open-label study with
approximately 12 patients planned for the phase IB portion of
the trial.
Dr. Giorgio Scagliotti presented data regarding afliber-
cept (VEGF-Trap), a recombinant fusion protein that binds
VEGFR-1, VEGFR-2, and placental growth factor (PlGF). In
early phase I and II studies, aflibercept demonstrated safety
and activity as monotherapy or in combination with chemo-
therapy.6 The VITAL phase III study completed accrual in
February 2010 and randomized patients receiving second-line
treatment to either docetaxel plus aflibercept versus docetaxel
plus placebo.
Dr. Robert Doebele summarized the trials involving
ramucirumab, an inhibitor of VEGFR-2. In a single arm
open-label phase II trial, chemotherapy-naive patients re-
ceived carboplatin/paclitaxel plus ramucirumab for up to six
cycles, followed by ramucirumab maintenance until disease
progression. Preliminary results indicate an overall response
rate (ORR) of 59% with an additional 45% of patients
achieving stable disease.7 Randomized studies of ramuci-
rumab in combination with chemotherapy are underway in
various countries in the first- and second-line settings with
planned biomarker analysis.
Dr. Harry Drabkin reviewed the role of semaphorins
and neuropilins (NRPs) in lung cancer. SEMA3F is a secreted
semaphorin that is down-regulated in NSCLC with potent
tumor suppressor activity and a direct effect on endothelial
cells to inhibit angiogenesis. NRPs competitively bind and
function as receptors for VEGF and other growth factors such
as SEMA3F and are up-regulated in NSCLC. When NRP
complexes with VEGF, cell migration and proliferation oc-
curs, whereas when it complexes with SEMA3F, tumorigen-
esis is inhibited. Therefore, strategies to up-regulate
SEMA3F and block NRP-VEGF binding are felt to be syn-
ergistic and may provide a novel therapeutic approach in the
treatment of lung cancer.8
Dr. Edward Garon discussed fosbretabulin (Combres-
tatin/CA4P), a VDA which acts as a reversible tubulin depo-
lymerizing agent that selectively disrupts the vascular endo-
thelial cell junctional protein, VE-cadherin. Fosbretabulin
targets abnormal blood vessels by acting on newly formed
cells that lack smooth muscle contact and was found to
enhance the activity of carboplatin/paclitaxel/bevacizumab in
xenograft models.9,10 In the phase II FALCON trial, patients
with nonsquamous NSCLC received carboplatin/paclitaxel/
bevacizumab fosbretabulin with an interim analysis reveal-
ing that the combination with fosbretabulin was well tolerated
with no overlapping toxicities.
Future Directions
Although bevacizumab remains the only angiogenesis
inhibitor that is FDA approved in the treatment of NSCLC,
there are a number of other angiogenesis inhibitors in clinical
development that have shown promising initial results. Ad-
ditional data are awaited from ongoing trials, including the
discovery of biomarkers that can predict which patients are
most likely to benefit from angiogenesis inhibition.
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